Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mike Paulden

Showing results (1-10 of 78) with videos related to

Pageof 8
Sort By:
Pharmacoeconomics|August 20, 2020
Correction to: Calculating and Interpreting ICERs and Net BenefitMike Paulden
Pharmacoeconomics|May 12, 2020
Why it's Time to Abandon the ICERMike Paulden
Expert Review of Pharmacoeconomics & Outcomes Research|May 12, 2017
Recent amendments to NICE's value-based assessment of health technologies: implicitly inequitable?Mike Paulden
Pharmacoeconomics|March 13, 2024
Reply to Comment on "A Framework for Fair Pricing of Medicines"Mike Paulden
Pharmacoeconomics|March 18, 2026
A Modern Approach for Constructing Decision Analytic Models in Microsoft ExcelMike Paulden
Pharmacoeconomics|May 12, 2020
Calculating and Interpreting ICERs and Net BenefitMike Paulden
Pharmacoeconomics|December 8, 2023
A Framework for the Fair Pricing of MedicinesMike Paulden
Pharmacoeconomics|December 15, 2025
Economic Consequences of Increasing the NICE Cost-Effectiveness ThresholdMike Paulden
Health Economics|March 26, 2011
Budget allocation and the revealed social rate of time preference for healthMike Paulden, Karl Claxton
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|June 3, 2017
Incorporating equity in economic evaluations: a multi-attribute equity state approachJeff Round, Mike Paulden
Pageof 8

Showing results (1-10 of 78) with videos related to

Sort By:
Pageof 8
Pharmacoeconomics|August 20, 2020
Correction to: Calculating and Interpreting ICERs and Net BenefitMike Paulden
Pharmacoeconomics|May 12, 2020
Why it's Time to Abandon the ICERMike Paulden
Expert Review of Pharmacoeconomics & Outcomes Research|May 12, 2017
Recent amendments to NICE's value-based assessment of health technologies: implicitly inequitable?Mike Paulden
Pharmacoeconomics|March 13, 2024
Reply to Comment on "A Framework for Fair Pricing of Medicines"Mike Paulden
Pharmacoeconomics|March 18, 2026
A Modern Approach for Constructing Decision Analytic Models in Microsoft ExcelMike Paulden
Pharmacoeconomics|May 12, 2020
Calculating and Interpreting ICERs and Net BenefitMike Paulden
Pharmacoeconomics|December 8, 2023
A Framework for the Fair Pricing of MedicinesMike Paulden
Pharmacoeconomics|December 15, 2025
Economic Consequences of Increasing the NICE Cost-Effectiveness ThresholdMike Paulden
Health Economics|March 26, 2011
Budget allocation and the revealed social rate of time preference for healthMike Paulden, Karl Claxton
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|June 3, 2017
Incorporating equity in economic evaluations: a multi-attribute equity state approachJeff Round, Mike Paulden
Pageof 8